2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease
Galasko D, Farlow M, Lucey B, Honig L, Elbert D, Bateman R, Momper J, Thomas R, Rissman R, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman H. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease. Alzheimer's Research & Therapy 2024, 16: 151. PMID: 38970127, PMCID: PMC11225352, DOI: 10.1186/s13195-024-01490-z.Peer-Reviewed Original ResearchConceptsOrally administered small moleculeFractional synthesis rateAscending dose studyDose-dependent loweringIRB-approved protocolEarly ADMini-Mental State ExamDose-dependent effectAlzheimer's diseaseBlood patchDouble-blindWell-toleratedCatheter placementPreclinical modelsLumbar punctureDose studyIntravenous infusionMild cognitive impairmentEvaluate safetyPlacebo participantsCognitive measuresStable isotope labeling kineticsActive drugClinical trialsADAS-Cog12
2023
Lobe‐specific changes in white matter volume and myelination following 6‐month 40 Hz gamma sensory stimulation in patients on the Alzheimer’s disease spectrum
Cimenser A, Da X, Hempel E, Malchano Z, Vaughan B, Megerian J, Hajos M. Lobe‐specific changes in white matter volume and myelination following 6‐month 40 Hz gamma sensory stimulation in patients on the Alzheimer’s disease spectrum. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.073143.Peer-Reviewed Original ResearchWhite matter volumeAlzheimer's diseaseWhite matterPlacebo groupTemporal lobeMatter volumeFrontal lobeParietal lobeWhite matter atrophyGray matter changesMRI T1 imagesTreatment group resultsMonth 3Month 6Neurological comorbiditiesT1w/T2w ratioMatter atrophyAD patientsMagnetic resonance imaging dataPathological changesOccipital lobePlacebo participantsMatter changesNeuronal activityTreatment groups
2017
Effects of acute alcohol intoxication on executive functions controlling self-regulated behavior
Spinola S, Maisto S, White C, Huddleson T. Effects of acute alcohol intoxication on executive functions controlling self-regulated behavior. Alcohol 2017, 61: 1-8. PMID: 28599712, DOI: 10.1016/j.alcohol.2017.02.177.Peer-Reviewed Original ResearchConceptsExecutive functionSelf-regulated behaviorRisk-taking behaviorExecutive functioningDose of alcoholPractice effectsHeavy drinkersBeverage conditionControl participantsAcute alcohol intoxicationMemory dataSignificant impairmentAlcohol intoxicationMixed-methods study designMethodological concernsDeficitsMemoryParticipantsSignificant interactionPlacebo participantsLow BACsDrinkersAlcohol consumption
2016
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016, 315: 2424-2434. PMID: 27299618, PMCID: PMC5617638, DOI: 10.1001/jama.2016.7602.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdverse eventsClinical trialsWeight lossObese adultsHigher oddsAdverse event-related treatment discontinuationSystematic reviewSignificant excess weight lossCumulative ranking (SUCRA) probabilitiesDiscontinuation of therapyExcess weight lossProportion of patientsManagement of obesityQuality of evidenceWeight loss agentsWeb of ScienceTreatment discontinuationCochrane CENTRALPharmacological treatmentMagnitude of decreaseGRADE criteriaDrug treatmentLiraglutideMAIN OUTCOMEPlacebo participants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply